Sopherion Therapeutics (Princeton, NJ) a late-stage oncology company with European and Canadian as a first-line therapy in combination with cyclophosphamide for patients with metastatic breast cancer, closed a $55M Series C financing. Participants include Zoticon BioVentures, Sprout Group, ProQuest, Canaan Partners, HealthCap, NewSpring Ventures, Commerce Health Ventures and Seaflower Ventures.